Hengdao Pathology Completes A+ Financing Round to Advance AI-Powered Pathology Solutions

VCBeat (WeChat ID: vcbeat) has learned that Shanghai-based Hengdao Medical Pathology Diagnostic Center (also known as “Hengdao Pathology”) recently completed its A+ round of financing. This round was led by SenseTime in conjunction with Tendence Capital, with China United Investment participating as a co-investor. The funds raised will be primarily allocated to the research and development of artificial intelligence in pathology, as well as the establishment of application scenarios.

Shanghai Hengdao Medical Pathology Diagnostic Center covers an area of 2,500 square meters and features comprehensive basic and molecular pathology diagnostic and technical platforms. Established in alignment with national policies on tiered diagnosis and treatment and medical consortiums, the Center is a specialized institution providing end-to-end pathology diagnostic services to medical institutions at all levels. As the first medical institution in China to obtain a license for an independent third-party pathology diagnostic center, Hengdao Pathology operates the largest single pathology laboratory in the country and is deeply involved in the formulation of relevant standards and regulatory documents in this field.

In recent years, with the rise of precision medicine, pathological diagnosis, recognized as the “gold standard” for disease diagnosis in the medical community, has seen its value further highlighted. AI-powered pathology has also emerged as a highly anticipated technological trend. Today, an increasing number of healthcare companies and related industry investors are vying to establish their presence, aiming to enhance the core competitiveness of their AI technologies. Hengdao Pathology is committed to building the infrastructure for the pathology industry in the era of artificial intelligence, providing pathologists with smarter and more convenient diagnostic assistance tools, thereby effectively supporting precise diagnosis and tiered diagnosis and treatment.

After two years of development and iteration, Hengdao Pathology has established pathological diagnosis as its core foundation. By focusing on two main pillars—the delivery of pathological diagnostic technologies and services, and the construction of infrastructure for the pathology industry—it has extended its reach into digital pathology, supporting services for primary care hospitals, the establishment of regional pathological diagnostic centers, the application of biogenetic technologies, the research and development of medical artificial intelligence, and integration with medical insurance coverage. This strategy has gradually formed a development structure characterized by “a central focus with multiple facets, offering coherent and in-depth expansion.”

Furthermore, Hengdao Pathology has garnered a substantial following in the industry for its chain pathology centers, collaborative pathology initiatives with primary care institutions, and dissemination of pathological technology knowledge, with its brand recognition increasingly highlighted by its technological advancements.

Internal and external pressures led to 2018 being dubbed the “capital winter,” leaving entrepreneurs and investors treading on thin ice. Nevertheless, the artificial intelligence industry bucked the trend that year, achieving continuous implementation across multiple sectors, including security, smart home, enterprise services, new finance, and general health. From a broader perspective, startups grounded in technology and dedicated to empowering industries have continued to attract capital favor. The deep integration of technology and industry may well usher in the next wave of economic development and technological iteration. Huidao Pathology seized the opportunities amidst the downturn, demonstrating its value through technology.

Ms. Wu Ronghui, Managing Partner at Tongdu Capital, stated to VCBeat that since its inception, Tongdu Capital has adhered to the investment philosophy of “technology-driven industry innovation.” By mastering cutting-edge technologies and deeply embedding itself within the industry, the firm carefully selects teams capable of leveraging technology to transform their respective sectors, meticulously supporting them in becoming future industry leaders and achieving success. Pathology is one of the key medical fields for AI application, where AI technology has been proven to significantly enhance the efficiency of pathological testing, alleviate the shortage of pathologists, and reduce the time required for diagnostics. Hengdao Pathology effectively integrates application scenarios, data, and algorithms to create a closed-loop AI ecosystem, while extending the expertise of pathology specialists to grassroots pathology departments and medical institutions. Tongdu Capital aligns with Hengdao Pathology’s development philosophy and has confidence in the team’s capabilities. We are committed to working alongside Hengdao Pathology to advance the intelligent transformation of pathological testing in China, thereby making medical services more accessible, precise, and efficient.